Marrow Therapeutics, a genetic medicines company based in Watertown, Massachusetts, launched on November 17, 2026, with $173 million in combined series A and B financing to develop bone marrow-targeted therapies for severe blood disorders.¹ Its lead candidate, MAR-101, is in investigational new drug application (IND)-enabling studies for sickle cell disease (SCD) and beta thalassemia.¹
Key facts
- Company: Marrow Therapeutics (Watertown, Massachusetts)
- Financing: $173 million total ($53 million series A; $120 million series B)
- Lead investors: Scion Life Sciences and venBio (series A); OrbiMed (series B)
- Platform: Transferrin Antibody Bioconjugate (TAB), targeting TfR1 in bone marrow
- Lead candidate: MAR-101 (BCL11A reduction to reactivate fetal hemoglobin)
- Indications: Sickle cell disease and beta thalassemia
- Stage: IND-enabling studies
- Clinical timeline: Clinical entry expected in the coming year, per Scion
- Leadership: Romesh Subramanian, president and CEO
- Advisors: Art Levin (board); Stuart Orkin (scientific advisory board)
“We’re at a pivotal moment in genetic medicine and its application in severe blood disorders—the field has validated key targets and shown that genetic approaches can work, but we need to solve the safety and accessibility challenges to truly transform patient outcomes,” said Romesh Subramanian, PhD, Marrow’s president and CEO, in a company press release.¹
Who invested in Marrow?
The $53 million series A was co-led by venBio and Scion Life Sciences, which founded Marrow.¹ OrbiMed led the $120 million series B. All series A investors took part, joined by new investors including RTW Investments, Surveyor Capital, Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital, and Columbia Threadneedle Investments.¹
Art Levin, founding chief scientific officer of Avidity Biosciences, has joined Marrow’s board. Stuart Orkin, David G. Nathan Distinguished Professor of Pediatrics at Harvard Medical School and a Howard Hughes Medical Institute investigator at Boston Children’s Hospital, has joined its scientific advisory board.¹ The leadership team also includes Tim Weeden as chief scientific officer, John Najim as chief operating officer and chief technology officer, and Gavriel Mullokandov as founder and vice president of corporate development.¹
How does Marrow’s platform work?
Marrow’s Transferrin Antibody Bioconjugate (TAB) platform uses engineered antibodies that target the transferrin receptor (TfR1) in bone marrow to deliver therapeutic payloads to bone marrow cells.¹ The company says its approach engages TfR1 while avoiding off-target effects, particularly the anemia risk that limits other TfR1-targeted approaches.¹ That class-level concern has been documented preclinically. In a 2013 study of TfR bispecific antibodies designed to cross the blood-brain barrier, researchers observed decreased circulating reticulocytes after dosing. Eliminating the antibodies’ Fc effector function partially rescued that decrease.²